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ABSTRACT 
 
Multiple sclerosis (MS) is a chronic demyelinating disease affecting the 
neurons of brain and spinal cord. In chronic MS lesions oligodendrocytes 
(the myelin synthesizing cells) precursor cells (OPCs) accumulate with loss 
of mature OLs, suggesting a differentiation block of OPCs. In MS patients 
during the active phase of the disease (poussè) the disruption of the blood 
brain barrier can allow serum antibodies and other molecules to reach the 
CNS, producing demyelination. 
Here we demonstrate that IgGs, isolated from MS patients during the acute 
phase, inhibit PMA-induced differentiation of OPCs by reducing the 
expression of the OLs differentiation markers in the human OL cell line, 
MO3-13.  In a more specific setting, in which differentiation is driven by the 
action of serotonin (5-HT) on its specific receptor (5-HT2aR subtype), IgGs 
from MS patients inhibit 5-HT-induced signalling. We also demonstrated, 
by flow cytometry experiments, the binding of 5-HT2aR with serum-IgG 
from a MS patient.  
In conclusion, these data demonstrate that MS-derived autoantibodies 
interfere and inhibit oligodendrocyte differentiation-induced by 5HT. The 
identification of a putative receptor targeted by IgGs present in the 
biological fluids of MS patients will pave the way to dissect the signalling 
pathway leading to demyelination in MS. 
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CHAPTER I 
INTRODUCTION 
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1.1. Multiple Sclerosis 
Multiple sclerosis (MS) is characterized by a chronic demyelinating 
inflammation, damaging the central nervous system (CNS) (1, 2). MS is the 
most common cause of disability in young adults. As in other chronic 
inflammatory diseases, the manifestations of MS change from a benign to a 
rapidly progressive and disabling form. Some indirect data suggest an 
autoimmune etiology for MS, perhaps triggered by a viral infection, in 
genetically susceptible individuals (3). Despite the number of studies on 
the disease and a multidisciplinary approach to the problem, the 
pathogenesis of MS is still obscure and the etiology is unknown. 
The term MS derives from multiple sclerotic areas visible in macroscopic 
examination of the brain. These lesions, called plaques, are easily 
distinguishable from the surrounding white matter. The plaques vary in 
size from 1-2 mm to several centimetres. The acute lesion of MS, which is 
rarely found in a post mortem examination, is characterized by infiltration 
of mononuclear cells (mainly T lymphocytes and macrophages) and loss of 
myelin (demyelination). Myelin (Figure 1), formed by glial cells named 
oligodendrocytes (OLs), constitutes the sheath that insulates nerve cell 
extensions, allowing the rapid and integral transmission of nerve impulses. 
With the progression of the disease the destruction of myelin sheaths 
causes blocking or slowing of nerve impulses. The inflammatory infiltrates 
appear to mediate the loss of the myelin sheath surrounding the axon 
cylinder. With the progression of the lesion, a large number of 
macrophages and microglial cells (phagocytes specialize in the CNS that 
derive from bone marrow) digest myelin fragments and astrocytes 
proliferate (gliosis). In chronic lesions are present a complete or nearly 
complete demyelination and dense gliosis (Figure1) (4). 
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Figure 1. Chronic lesions of multiple sclerosis in Humans. 
Panel A - An electron micrograph of a chronic active lesion shows a myelinated fiber undergoing 
demyelination. The arrow shows myelin droplets on the macrophage surface being internalized by 
the cell. The fiber is invested by a microglial cell, which is engaged in the phagocytosis of myelin 
droplets as they are divested from the myelin sheath. The end product of this process is shown in 
Panel B (toluidine blue stain). Panel B - An area from a chronic silent gliotic lesion is made up of 
astroglial scar tissue, in which intact demyelinated axons (light profiles) are embedded; 
mitochrondria can be seen within the axons; the smaller nuclei belong to microglial cells, but no 
oligodendrocytes are present. Panel C - An electron micrograph with a field similar to that in Panel 
B shows large-diameter demyelinated axons (A) within the glial scar; an astroglial-cell body is at the 
upper right. Panel D - (toluidine blue stain) A biopsy specimen from a patient with secondary 
progressive multiple sclerosis shows an area of remyelination (shadow plaque) in which the myelin 
sheaths of many axons are disproportionately thin and OLs are overabundant. These cells are 
probably oligodendroglial precursor cells recently recruited into the lesion. Panel E - An electron 
micrograph shows remyelination; the myelin sheaths are thin in comparison to the diameters of the 
axons, and two OLs are evident (OL).Panel F - (Luxol fast blue and periodic acid–Schiff) There is an 
abrupt transition at the edge of the chronic MS lesion. The myelin internodes (blue) terminate 
sharply at the demyelinated plaque. OLs are present (arrows) up to the edge of the lesion, but not 
within the lesion. Rod cells (microglia) are lined up along the boundary. A denotes axon, and As 
astrocyte. 
(Elliot M. Frohman et al. –Multiple Sclerosis-The plaque and its pathogenesis-N Engl J Med 2006). 
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1.1.1. Pathogenesis 
MS can be considered the result of complex multifactorial interactions 
between genetic and environmental factors. Several studies suggest that 
MS is an immune-mediated disease related to T lymphocytes action and 
induced by external and unknown agents, such as viruses and bacteria, in 
selected subjects. Most researchers seem to agree that the demyelination 
process includes at least three main factors:  
• a particular immunogenetic pattern; 
• an immunopathologic mechanism; 
• environmental factors. 
 
IMMUNOGENETIC FACTORS  
The evidence related to the influence of genetic factors in the pathogenesis 
of MS derives from studies of families and twins (5-8). These studies have 
shown that the disease risk is higher in the biologically related family 
members with MS patients, compared to the general population (9). These 
findings also suggest a common sharing of exposure to environmental risk 
factors during critical periods of risk (childhood and adolescence).  
 
IMMUNOPATHOLOGICAL MECHANISM 
MS seems to be a disease with autoimmune pathogenesis and it is 
mediated, at least in part, by T lymphocytes. In the autoimmune diseases 
there is an alteration of the immune system, autoreactive to endogenous 
self-peptides. In MS the myelin is not more recognized as self-peptide (10-
12). Normally, in our immune system the T cells play a key role in defence 
against foreign pathogens, such as viruses, bacteria and allergens. In MS, 
the T cells attack the myelin of the CNS (13-16). 
Previous studies have showed that peptide sequences of very common 
viral agents, such as Epstein Barr virus (EBV) (17, 18), influenza virus type 
5-HT2a receptor pathway in oligodendrocyte differentiation 
9 
 
A (19), human papilloma virus (HPV) (20) and human herpes virus type 6 
(HHV-6) (21, 22) are very similar to Myelin Basic Protein (MBP). Another 
virus, John Cunningham Virus (JCV), is a type of human polyomavirus 
(formerly known as papovavirus) and is genetically similar to BK virus and 
SV40. It was discovered in 1971 and named with the two initials of a 
patient (JC) with progressive multifocal leukoencephalopathy. This virus is 
able to infect OLs and has been shown to be reactivated in MS patients 
treated with interferon (23). The inflammatory reaction is associated with 
up-regulation of several Th1 cytokines, including interleukin 2 (IL-2), 
interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α) that 
were found in the cerebrospinal fluid (CSF) from patients with the disease 
(24, 25). The endothelial cells of the brain and spinal cord, triggered by 
demyelinating lesions, express adhesion molecules, fibronectin, the 
receptor for urokinase plasminogen activator (uPAR), the MHC class II 
molecules, chemokines and stress proteins (26). Magnetic resonance 
imaging (MRI) studies in the early stages of disease suggest that most of 
the lesions are preceded by focal destruction of blood brain barrier (BBB); 
therefore, this condition would facilitate entry of autoreactive T cells and 
antibodies inside the CNS (27). Recently, in experimental models of 
encephalomyelitis (EAE) it has been shown that the breaking of the BBB is 
initiated by memory T cells expressing CCR-6, the receptor for the chemo 
attractant molecule CCL-20. These cells escape from choroid plexus 
vessels, penetrate into stroma and cross the epithelial-choroid plexus 
barrier (28). The histopathological effect of these inflammatory 
mechanisms is the demyelination, which is the formation of a plaque, 
indicating damage to the myelin sheath. The neuron, therefore, devoid of 
the myelin sheath, loses the capability to transmit nerve signals leading to 
the appearance of a sign or a symptom. Neuropathological studies of MS 
lesions have clearly demonstrated a remyelination process, but this process 
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is incomplete in chronic lesions and usually limited to the edges of 
demyelinating plaques. 
 
ENVIRONMENTAL FACTORS 
Several epidemiological data suggest the intervention of environmental 
factors in the genesis of MS. Environmental factors proposed as possible 
risk factors of MS are: 
• specific or common bacteria or virus, 
• heavy metal poisoning, 
• industrial pollution, 
• hygiene, 
• diet, 
• climate. 
 
The viruses mostly investigated are: HHV-6, for its neurotrophism (21, 22), 
Epstein-Barr virus according to an action characterized by “molecular 
mimicry” (17, 18) and LM7 retrovirus, know as “multiple sclerosis 
associated retrovirus” (MSRV) (29, 30). Nevertheless, no viral agent has 
been conclusively linked to MS. It is likely that various infectious agents, 
also non-specific, induce, under certain circumstances, an immune 
response against self-antigens (31).  
 
1.1.2. Clinical manifestations 
The symptoms of MS are extremely various and not specific to the disease. 
In fact, many diseases such as cancer, stroke, systemic lupus 
erythematosus (SLE), vasculitis and other less severe diseases have, at 
least in part, common signs and/or symptoms with MS (32). The 
appearance of the disease can be sudden or slow. The symptoms at onset 
can be severe or so slight not to require medical attention even after 
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months from the onset. The nature of the symptoms depends on the lesion 
location (or plaque) in CNS. The most common symptoms at onset include 
weakness in one or more limbs, blurred vision, due to optic neuritis, 
abnormal sensitivity, diplopia and ataxia. In order to standardize the 
terminology to describe the clinical course and the subtypes of the disease, 
it has been created a task force of 215 experts, members of the 
international MS scientific community (33), which identified four types of 
disease: 
RELAPSING-REMITTING MS: is the most common form of MS in the 
people under 40 years and it represents the 45-50% of people with MS. 
The subjects are struck by acute attacks, also named exacerbations, 
followed by periods of remission, during which the patients fully or 
partially recover. This clinical variant evolves in 80% of cases in the 
secondary progressive form. 
SECONDARY PROGRESSIVE MS: characterized by a continuous disease 
progression after a period of time attributable to the relapsing-remitting 
type, with or without relapses or remissions. The recovery after 
exacerbations is incomplete, resulting in a progressive deterioration of 
physical conditions over time. It affects approximately 25-30% of patients 
with MS. 
PRIMARY PROGRESSIVE MS: gradual progression of the disease from its 
onset. The signs and symptoms accumulate gradually over time without 
the appearance of a real attack and without remissions, but rarely causing 
permanent disability, because the course is very slow. This form is more 
common in subjects presenting their first symptoms after age 40 
(approximately 10-15% of patients with MS). 
PROGRESSIVE RELAPSING MS: the patients with a primary progressive 
MS may have relapses. The intervals between relapses are characterized by 
5-HT2a receptor pathway in oligodendrocyte differentiation 
12 
 
a continuous progression of the disease, unlike relapsing-remitting MS. It 
affects 2-5% of subjects with MS. 
A BENIGN DISEASE indicates the lack of detection of neurological deficit 
15 years from onset with complete remission (10% of patients). On the 
contrary, MALIGNANT DISEASE is characterized by a rapid and progressive 
course that causes multiple neurological deficits or death in a short period 
of time (5% of patients). 
 
1.1.3. Diagnosis 
No definitive diagnostic tests for MS are currently available. Therefore, to 
reach a definitive diagnosis it is necessary to use different tools derived 
from clinical analysis (34), laboratory (35) and instrumental tests (36, 37). 
1) CLINICAL DIAGNOSIS analyzes: 
• Patient medical history; 
• Evidence of altered sensibility, impaired strength and vision 
disturbances; 
• Symptoms/signs attributable to white matter lesions are not 
justified by other diseases; 
• Spatial dissemination of lesions with clinical signs referable 
to 2 or more lesions; 
• Symptoms/signs attributable to the temporal dissemination 
of the lesions: two or more relapses; 
2) LABORATORY DIAGNOSIS is based on CSF investigations 
(inflammatory and autoimmune disorders), assaying the 
intrathecal synthesis of Immunoglobulins G (IgG) and the 
presence of oligoclonal Ig bands. 
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3) INSTRUMENTAL DIAGNOSIS: 
• Magnetic Resonance Imaging (MRI) detects pathological foci 
in the brain stem, cerebellum and spinal cord and the 
presence of lesions in the corpus callosum and the ventricles.  
• Computerized Axial Tomography (CAT) shows less dense 
areas around the ventricles corresponding to the plaques 
where the myelin is lost. 
• Testing of Evoked Potentials (EP) measures the transmission 
time of sensory messages that travel through the nerves. 
In MS the diagnostic procedure is rather long and tortuous and at present 
the only diagnostic support provided by the laboratory is based on analysis 
of intrathecal IgG synthesis and research of oligoclonal Ig bands. 
The CSF constitutes the extra-cellular component of the CNS and it is 
separated from the systemic circulation only through the BBB. The IgG 
dosage in CSF and serum appears of same clinical interest. Numerous 
formulas have been used to distinguish the IgG synthesized locally by those 
in serum, which may enter the CNS passively through an altered BBB. An 
useful formula expresses the relationship between IgG and CSF albumin 
and IgG and serum albumin ("index LCS-IgG”). This quantitative analysis is 
simple and rapid, but not specific. Therefore, a more specific test is based 
on the research of oligoclonal Ig bands. 
 
1.2. Oligodendrocytes 
Glial cells, commonly called neuroglia or simply glia, are non-neuronal cells 
that maintain homeostasis, form myelin, and provide support and 
protection for the brain's neurons. It is divided in microglia and macroglia 
(composed by astrocytes, OLs, ependymal cells and radial glia in CNS). 
The most abundant type of macroglia cell, astrocytes (also called astroglia) 
have numerous projections that anchor neurons to their blood supply. 
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They regulate the external chemical environment of neurons by removing 
excess ions, notably potassium, and recycling neurotransmitters released 
during synaptic transmission. 
Ependymal cells, also named ependymocytes, line the cavities of the CNS 
and make up the walls of the ventricles. These cells create and secrete CSF 
and beat their cilia to help circulate CSF. 
OLs are cells that coat axons in the CNS with their cell membrane forming a 
specialized membrane differentiation called myelin, producing the so-
called myelin sheath. The myelin sheath provides insulation to the axon 
that allows electrical signals to propagate more efficiently (Figure 2).  
Oligodendroglia derive during development from oligodendrocyte 
precursor cells (OPCs), which can be identified by their expression of a 
number of antigens, including the ganglioside GD3 (38, 39), the NG2 
chondroitin sulfate proteoglycan, and the platelet-derived growth factor-
alpha receptor subunit (PDGF-αR). 
 
 
Figure 2. Glia cells. An oligodendrocyte simultaneously wrapping multiple axons with a myelin 
sheath. Also shown are nodes of Ranvier, which are small unmyelinated axonal regions. 
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1.2.1. Myelin 
The myelin sheath around most axons constitutes the most abundant 
membrane structure in the vertebrate nervous system. Its unique 
composition (richness in lipids and low water content allowing the 
electrical insulation of axons) and its unique segmental structure 
responsible for the saltatory conduction of nerve impulses allow the 
myelin sheath to support the fast nerve conduction in the thin fibers in the 
vertebrate system. High-speed conduction, fidelity of transfer signaling on 
long distances, and space economy are the three major advantages 
conferred to the vertebrate nervous system by the myelin sheath, in 
contrast to the invertebrate nervous system where rapid conduction is 
accompanied by increased axonal calibers. 
Myelin proteins, which comprise 30% dry weight of myelin, are for most of 
the known ones, specific components of myelin and OLs. 
The major CNS myelin proteins, MBP and Proteolipidic Protein (PLP) (and 
isoform DM-20), are low-molecular-weight proteins and constitute 80% of 
the total proteins. Another group of myelin proteins, insoluble after 
solubilization of purified myelin in chloroform-methanol 2:1, have been 
designated as the Wolfgram proteins, since their existence was suspected 
already in 1966 by Wolfgram. These proteins comprise the 2’,3’-cyclic 
nucleotide-3’-phosphohydrolase (CNP) and other proteins (40). 
 
1.2.2. Myelination 
Myelination consists of the formation of a membrane with a fixed 
composition and specific lipid-protein interactions allowing membrane 
compaction and the formation of the dense and intraperiodic lines of 
myelin. Therefore, myelination also needs activation of numerous enzymes 
of lipid metabolism necessary for the synthesis of myelin lipids, of 
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synthesis and transport of specific protein components of myelin or their 
mRNAs to the OLs processes. 
These are the sequential steps governing myelination: 
1. the migration of OLs to axons that are to be myelinated, 
and the fact that axons and not dendrites are recognized; 
2. the adhesion of the OL process to the axon; 
3. the spiraling of the process around the axon, with a 
predetermined number of myelin sheaths and the 
recognition of the space not to be myelinated, i.e., the 
nodes of Ranvier (40). 
In the first step, the pre-oligodendroglial multiprocessed cells settle along 
the fiber tracts of the future white matter, maintaining the ability to divide. 
Indeed, mitoses are present in the interfascicular longitudinal glial rows 
(41). Second, these pre-OLs become immature OLs, characterized by the 
acquisition of specific markers and ready for myelination. 
 
1.2.3. Remyelination 
The OLs and the myelin sheath are the main targets of the pathological 
process in MS. The loss of OLs involves the demyelination, and thus a 
considerable loss of efficiency of axons to conduct impulses (1, 2). After the 
demyelination a spontaneous regenerative or healing process by which 
new myelin layers are formed around demyelinated axons, is taking place. 
This process is named remyelination, which allows axons to restore 
efficient conduction of nerve impulses. In the first stage of the disease, 
when the axonal degeneration is not significant, the demyelinating injury is 
compensated by remyelinization (42). 
The remyelination is mediated by a population of stem cells abundantly 
distributed in the adult CNS. These cells are the OPCs, and the 
inflammation is vital to stimulate, inside of the lesion, the production of 
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factors that promote the recruitment of these precursors (43). Soon the 
demyelination area is filled by the OPCs that have the ability to proliferate 
and differentiate into mature OLs, producing new myelin sheath around 
the demyelinated axons (44, 45). The continuous maturation of these cells 
ensures a continuous process of myelin formation. This correcting 
mechanism is not perfect and limited to the early stages of the disease. 
In MS it is not known whether the remyelination is slowed or blocked. The 
failed remyelination in MS has been associated with limited availability, 
migratory capability or myelination of the OPCs. Previous studies have 
shown that in chronic demyelinating lesions in MS patients there is a small 
number of pro-OLs and an increased number of OPCs, suggesting the 
presence of defective mechanism in the OPCs maturation (46, 47). 
 
1.2.4. Oligodendrocyte proliferation and differentiation 
The growth and the development of neuronal cells are controlled by a set 
of different factors: NGF, IGF II, laminin, fibronectin, collagen and adhesion 
molecules such as N-CAM and cadherins (48). Moreover, in the adult brain 
the turnover and the replacement of OLs, as well as the remyelination 
process, are phenomena that occur continuously. The brain contain 
endogenous OPCs with the ability to proliferate and differentiate into 
mature OLs, through the stages of Pro-OL and immature OL, producing new 
myelin sheath around the demyelinated axons (Figure 3) (49, 50). The 
oligodendrocyte precursors are present during the development of the 
nervous system, but some of them remain in the fully developed brain. 
They constitute the largest group of cells subjected to mitosis in the adult 
brain. 
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Figure 3. Immunophenotype and morphology of perinatal oligodendrocyte lineage cells in 
culture. 
The name of the cell type is listed along the top, with the most immature stage, the pre-O-2A or pre-
progenitor, at the left and the most differentiated stage, the mature oligodendrocyte, at the right. 
 
The generation of OPCs by neural stem cells is the result of interaction of 
local extrinsic induction factors (SHH, FGF2, PDGF, IGF1, neurotrophins) 
(51-53) with proteins of the intrinsic transcription machinery of CNS (54). 
The neurotrophins (NGF, BDNF, NT-3, NT-4/5) are small secreted proteins 
in the nervous system and are important in the differentiation, migration, 
proliferation and activation of cells of the CNS. In fact, BDNF and NT3 are 
required for survival and myelination (55). The first transcription factors 
in the differentiating of OPCs in spinal cord and forebrain (therefore used 
as markers for early OPCs) are Olig-1 and Olig-2, members of the basic 
helix-loop-helix (bHLH) family (54). Olig-2 leads to the generation of OPCs, 
while Olig1 seems involved in the survival and maturation of OPCs. 
A second group of transcription factors crucially involved in OPC 
differentiation includes members of the Sox family. In particular, Sox8, Sox 
9 and Sox10 are expressed in OPCs directly after induction of OL lineage 
and, therefore, are also frequently used as markers for early OPCs. Sox5 
and Sox6 are involved in the progression of OPCs differentiation towards 
more mature stages (56,57). In addition, three members of the 
homeodomain transcription factor family, Nkx2.2, Nkx6.1 and Nkx6.2 (53), 
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along with two members of the Zinc-finger superfamily of transcription 
factors: Myt1 and YinYang1, seem to play a role in the differentiation of the 
oligodendrocyte progenitors (58, 59). 
 
1.2.5. Factors influencing oligodendrocyte maturation and survival 
Many growth factors have been found to be involved in the proliferation, 
differentiation, and maturation of the oligodendrocyte lineage. 
 
- PDGF. Platelet Derived Growth Factor (PDGF) is synthesized 
during development by both astrocytes and neurons. In vitro, PDGF, a 
survival factor for oligodendrocyte precursors, is a potent mitogen for 
OPCs, although it triggers only a limited number of cell divisions. PDGF is 
also a survival factor for oligodendrocyte progenitors, as recently 
demonstrated by the impaired OL development in the PDGF-α deficient 
mice. In these mice, there are profound reductions in the numbers of 
PDGFR-α progenitors and OLs in the spinal cord and cerebellum, but less 
severe reductions of both cell types in the medulla. Infusion of PDGF into 
the developing optic nerve in vivo greatly reduces apoptotic cell death 
(60). PDGF also stimulates motility of oligodendrocyte progenitors in vitro 
and is chemo attractive. 
 
- BASIC FGF. Basic Fibroblast Growth Factor (bFGF) (also called 
FGF 2) is also a mitogen for neonatal oligodendrocyte progenitors. It up 
regulates the expression of PDGFR-a and therefore increases the 
developmental period during which oligodendrocyte progenitors or pre-
OLs are able to respond to PDGF (61). Pre-OLs can even revert to the 
oligodendrocyte progenitor stage when cultured with both PDGF and bFGF. 
This inhibition of oligodendrocyte differentiation can be overridden by the 
presence of astrocytes. bFGF is present in the developing nervous system 
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in vivo. The levels of expression of mRNA for the high-affinity bFGF 
receptors-1, -2, and -3 are differentially regulated during lineage 
progression (62); this pattern of expression could provide a molecular 
basis for the varying response of cells to a common ligand that is seen 
during development. 
 
- IGF-1. Insulin-like growth factor I (IGF-I) stimulates 
proliferation of both oligodendrocyte progenitors and pre-OL O41 positive 
cells, and IGF receptors have been shown to be present on cells of the 
oligodendrocyte lineage (63). IGF-I is also a potent survival factor for both 
oligodendrocyte progenitors and OLs in vitro. The morphology of 
myelinated axons and the expression of myelin specific protein genes have 
been examined in transgenic mice that overexpress IGF-I and in those that 
ectopically express IGF binding protein-1 (IGFBP-1), a protein that inhibits 
IGF-I action when present in excess. The percentage of myelinated axons 
and the thickness of the myelin sheaths are significantly increased in IGF-I 
transgenic. An alteration in the number of OLs is seen but cannot 
completely account for the changes in the increase in myelin gene 
expression. IGFBP-1 transgenic mice have a decreased number of 
myelinated axons and thickness of the myelin sheaths. IGF-I could be 
involved in both the increase in OLs number and in the amount of myelin 
produced by each OL (64). 
 
- NT-3. Neurotrophin-3 (NT-3) is a mitogen for optic nerve 
oligodendroglial precursors only when added with high levels of insulin, 
with PDGF, or with their combination. Astrocytes express NT-3 in optic 
nerve. NT-3 promotes also OL survival in vitro (65). The TrkC tyrosine 
kinase or TrkC receptor for NT-3 is expressed in OLs. Mice lacking NT-3 or 
its receptor TrkC exhibit profound deficiencies in CNS glial cells, 
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particularly in oligodendrocyte progenitors; there is an important 
reduction in the spinal cord diameter, thereby suggesting that cell 
populations other than neurons are affected (66). 
It was recently shown that NT-3 in combination with brain-derived 
neurotrophic factor (BDNF) is able to induce proliferation of endogenous 
oligodendrocyte progenitors and the subsequent myelination of 
regenerating axons in a model of contused adult rat spinal cord (67). 
 
- GGF. The glial growth factor (GGF), a member of the 
neuregulin family of growth factors generated by alternative splicing, 
including Neu, heregulin, and the acetylcholine receptor-inducing activity 
(ARIA), is a neuronal factor, mitogenic on oligodendrocyte precursors; it is 
also a survival factor for these cells. It delays differentiation into mature 
OLs (68). In mice lacking the family of ligands termed neuregulins, OLs in 
spinal cord failed to develop (69). This failure can be rescued in vitro by 
the addition of recombinant neuregulin to explants of spinal cord. In the 
embryonic mouse spinal cord, neuregulin expression by motoneurons and 
the ventral ventricular zone is likely to exert an influence on early OPCs. 
Neuregulin is a strong candidate for an axon-derived promoter of 
myelinating cell development. 
 
- CNTF. The ciliary neurotrophic factor (CNTF) can also act as 
comitogen with PDGF. Animals deficient in CNTF have a reduced number of 
mitotic glial progenitors. CNTF also promotes OL survival in vivo (60). 
 
- IL-6. Interleukin (IL-6) may also act on OL survival as well as 
leukemia inhibitory factor (LIF) and a related molecule (50). 
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- TGF-β. In vitro, transforming growth factor (TGF-β) inhibits 
PDGF-driven proliferation and promotes differentiation of oligodendrocyte 
progenitors (71). 
 
1.3. Serotonin 
Serotonin or 5-hydroxytryptamine (5-HT) is a monoamine 
neurotransmitter. Biochemically derived from tryptophan, and it is 
primarily found in the gastrointestinal (GI) tract, platelets, and in 
the central nervous system (CNS) of animals including humans. 
5-HT signaling pathways integrate not only basic physiology, but also 
essential brain functions, including sensory processing, cognitive control, 
emotion regulation, autonomic responses, and motor activity. It is a target 
of many physiologic regulators, including modulators of gene transcription, 
neurotrophic peptides, and steroids as well as psychotropic therapeutics, 
which impact the formation and activity of 5-HT subsystems.  
Serotonin (5-HT) is synthesized from the amino acid l-tryptophan by the 
rate-limiting enzyme l-tryptophan-hydroxylase (TPH), resulting in the 
formation of 5-hydroxytryptophan (5-HTP). 5-HT is subsequently obtained 
by removal of a carboxyl group catalyzed by the enzyme 5-hydroxy-
tryptophan-decarboxylase. 5-HT is, like other neurotransmitters, stored in 
storage and release vesicles via the vesicular monoamine transporter 
(VMAT). When released in the synapse, serotonin exerts its effects through 
16 distinctive 5-HT receptors. Furthermore, 5-HT reuptake in the 
presynaptic neuron occurs via the serotonin transporter (5-HTT) (72). 
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Figure 4. Serotonin main signaling pathways. 
 
1.4. Serotonin receptors 
Serotonin (5-hydroxytryptamine; 5-HT) receptors are a family of G protein 
coupled receptors (GPCRs) and ligand-gated ion channels (5-HT 3) found 
in the central and peripheral nervous systems where they mediate 
neurotransmission. 5-HT receptors influence various processes and are 
hence a primary target of several drugs, including many antidepressants, 
antipsychotics, anorectics, antiemetics, and hallucinogens.  
GPCRs are characterized by seven membrane-spanning helices with an 
extracellular amino-terminus, an intracellular carboxy-terminus, and three 
intracellular and three extracellular loops connecting each of the 
transmembrane segments. Binding of an agonist to its GPCR leads to 
conformational changes in the receptor that induce the dissociation and 
activation of a receptor-specific heterotrimeric G protein into its α- and βγ- 
subunits.  
The seven transmembrane domain (7TMD) serotonin receptors are 
coupled to diﬀerent G proteins. The 5-HT1 receptors couple to Gαi /Gαo 
proteins; the 5-HT2 receptors couple to Gαq proteins; the 5-HT4 , 5-HT6 
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and 5-HT7 receptors couple to Gαs proteins, and the 5-HT5 receptors are 
related to Gαi /Gαo proteins. 
Activation of Gαs coupled receptors leads to the stimulation of adenylyl 
cyclases elevating cyclic AMP (cAMP), which as a second messenger 
interacts with other proteins including ion channels and activating the 
protein kinase A (PKA). This phosphorylating enzyme also activates cAMP-
responsive transcription factors like CREB modifying gene expression. The 
interaction with other exchange proteins directly activated by cAMP leads 
to alternative signaling cascades besides the classical PKA. The interaction 
with Gαi leads to inhibition of adenylyl cyclases, decreasing production of 
cAMP. 
The activation of Gαq/11 coupled receptors lead to the hydrolysis of 
membrane phosphoinositides resulting in the formation of diacyl glycerol 
(DAG) and inositol phosphates (IP3). IP3 can interact with the calcium 
reservoirs, elevating intracellular levels and activating protein kinase C. 
Serotonin receptors may also be coupled to Gα12/13 , mediating structural 
changes within the cell through activation of the Rho signaling pathway. 
The G ßγ dimeric subunit can interact with a variety of enzymatic eﬀectors 
within the cell, like their action on gated ion channels, regulation of 
particular isoforms of adenylyl cyclase and phospholipase C, and 
phosphoinositide-3-kinase isoforms (and ERK signaling) (73). 
 
1.4.1.  5-HT2a receptor 
Serotonin 5-HT2a receptors are important for mediating a large number of 
physiologic processes both in the periphery and in the central nervous 
system. These processes include platelet aggregation, smooth muscle 
contraction, and the modulation of mood and perception. Most of these The 
5-HT2 class that is divided into 5-HT2a, 5-HT2b, and 5-HT2c.  
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Figure 5. 5-HT2 receptors signaling.  
Main pathways of intracellular signaling for these serotonin receptors subtype involve rupture of 
membrane phospholipids, particularly with phospholipase C (PLC) producing diacylglycerol (DAG) 
and inositol 1,4,5-trisphosphate (IP3) from phosphatidylinositol 4,5-bisphosphate (PIP2). These 
second messengers activate protein kinase C (PKC) which in time may activate the extracellular 
signal-regulated kinases 1 and 2 (ERK1/2) 
 
A large number of drugs mediate their actions, at least in part, by 
interactions with 5-HT2a receptors. These include hallucinogens, atypical 
antipsychotic drugs and antidepressants.  
The 5-HT2a receptor activates PLC through Gq and leads to an 
accumulation of IP3, di-acylglycerol (DAG) and activation of protein kinase 
C (PKC). Increase in cytoplasmic IP3 causes a release of calcium from 
intracellular endoplasmic reticulum stores, a characteristic activation 
signature of many GPCRs. This cascade has been the most studied and is 
perhaps the most important signal transduction pathway regulated by this 
receptor.  
In addition to initiating intracellular signal transduction cascades, agonist 
activation of GPCRs also triggers cellular and molecular mechanisms that 
lead to the attenuation of receptor signaling. Thus, GPCR responsiveness to 
agonist-induced stimulation wanes over time, a process termed 
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desensitization. Other regulatory phenomena include resensitization, a 
recovery of receptor responsiveness following desensitization, and down-
regulation, a reduction in receptor number.  
 
1.4.2. 5-HT2a receptor desensitization and the role of kinases 
Desensitization is an adaptive mechanism by which cells regulate receptor 
responsiveness to repetitive environmental stimuli. Two major patterns of 
rapid GPCR desensitization have been characterized, homologous or 
agonist-specific, and heterologous or agonist-nonspecific. Homologous 
desensitization refers to the attenuation of a cell’s response to only that 
agonist. For example, a cell exposed to a 5-HT2a receptor agonist would, 
over time, become desensitized to repeated exposure to the same 5-
HT2a receptor agonist. In contrast, heterologous desensitization is the 
attenuation of the response to multiple distinct agonists acting at different 
receptor types following stimulation by a single agonist. Thus, exposure of 
a cell to a 5-HT2a receptor agonist may result in the desensitization of the 
cells responsiveness to an agonist with activity at another GPCR. In both 
homologous and heterologous desensitization, phosphorylation of the 
intracellular domains of GPCRs is thought to be essential. G protein-
coupled receptor kinases (GRKs) and arrestins are thought to be involved 
in mediating homologous desensitization while the second messenger-
dependent kinases, protein kinase A (PKA) and protein kinase C (PKC), are 
typically involved in heterologous desensitization. 
The mechanism of 5-HT2a receptor desensitization is incompletely 
understood. For some time though, it has been clear that 5-HT2a receptors 
may be desensitized following PKC activation, though cell-type specific 
effects have been noted. Infact it has been demonstrated that PKC 
activation is necessary for 5-HT-mediated 5-HT2a receptor internalization 
and is sufficient to bring about receptor endocytosis (74). 
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CHAPTER II 
OBJECTIVES 
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In chronic demyelinating MS lesions it was found a significant reduction of 
mature differentiated cells and an increased number of precursors, 
suggesting the presence of a block of the maturation process of OPCs. 
However, a possible mechanism leading to this differentiation block has 
not been clarified. 
 Recent evidence indicates that higher or unbalanced ROS production can 
be involved in the pathogenesis of several diseases affecting the CNS, 
including MS. In fact, the OLs and their precursors are highly sensitive to 
oxidative stress, for the large amount of oxygen consumed, low levels of 
cellular antioxidant defence systems and high intracellular iron content.  
Therefore, an unbalance between ROS production and elimination and 
alteration of redox-sensitive signalling may be an important factor leading 
to the maturation block of OPCs observed in MS lesions (79). 
 Our research group for several years has been studying the cellular and 
molecular mechanisms of redox signal transduction in several conditions, 
such as systemic sclerosis (scleroderma), neuronal degeneration, and 
cerebral and renal ischemia reperfusion. In all these conditions, the 
unbalance between ROS production and scavenging was critical for the 
initiation and progression of the disease (77).  
 On the basis of this information , we wish to dissect the MS pathogenesis 
by analysing : 1. The impact of ROS signalling on the differentiation of Ols: 
2. The presence in the serum of MS patients of molecules interfering with 
OLs differentiation 
The specific aims of this study are the following: 
• Molecular analysis of OLs differentiation induced by phorbol esters 
(PMA) 
• Analysis of the biological effects of immunoglobulins (Igs) isolated  
from MS in the active phase (Poussè) and in quiescent phase (Not 
Poussè);  
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• Molecular analysis of 5-HT2a signalling in oligodendrocyte 
differentiation  
• Interference between MS IgGs isolated from  serum of MS patients 
and 5-HT2a induced differentiation of OLs. 
5-HT2a receptor pathway in oligodendrocyte differentiation 
30 
 
CHAPTER III 
MATERIALS AND 
METHODS 
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3.1 Cell cultures 
M03-13 CELLS - The M03-13 cells are an immortal human-human 
hybrid cell line with the phenotypic characteristics of primary OLs, derived 
from the fusion of a 6-thioguanine-resistant mutant of a human 
rhabdomyosarcoma with OLs obtained from adult human brain. They were 
grown in Dulbecco’s Modified Eagles Medium (DMEM; GIBCO Invitrogen), 
containing 4.5g/L glucose (GIBCO, Auckland, New Zealand), supplemented 
with 10% Foetal Bovine Serum (FBS; Sigma S. Louis, USA), 100 U/ml 
penicillin and 100 μg/ml streptomycin. The cells were kept in a 5% CO2 
and 95% air atmosphere at 37° C. 
The cells were differentiated in FBS-free DMEM, supplementing with 100 
nM of Phorbol-12-Myristate-13-Acetate (PMA; Sigma-Aldrich). The cells 
were kept in a 5% CO2 and 95% air atmosphere at 37° C for 30 minutes, or 
1day (pro-differentiation conditions) or 4 days (mature OLs). The 
differentiated cells express markers of mature OLs such as MBP, 
Proteolipidic Protein (PLP) and 2’,3’-cyclic nucleoside 3’-
phosphodiesterase (CNPasi). These cells represent an excellent model to 
study the maturation and differentiation process of oligodendrocyte 
precursors. 
HEK293 CELLS - HEK293 is a cell line derived from human 
embryonic kidney cells, of a healthy, aborted fetus, grown in tissue culture. 
This particular line was initiated by the transformation and culturing of 
normal HEK cells with sheared adenovirus 5 DNA. The transformation 
resulted in the incorporation of approximately 4.5 kilobases from the viral 
genome into human chromosome 19 of the HEK cells. Cells were grown in 
Dulbecco’s Modified Eagles Medium (DMEM; GIBCO Invitrogen), containing 
4.5g/L glucose (GIBCO, Auckland, New Zealand), supplemented with 10% 
FBS (Sigma S. Louis, USA), 100 U/ml penicillin and 100 μg/ml 
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streptomycin. The cells were kept in a 5% CO2 and 95% air atmosphere at 
37°C. 
 
3.2 5-HT and PMA treatments 
HEK-293 and M03-13 cells, grown to semi confluence in 60mm dishes in 
FBS-free DMEM 4.5g/L glucose, were stimulated for 15 minutes with 5µM 
of Serotonin (5-HT), and after the differentiation markers were analyzed 
by Western-blot or by flow cytometric analysis. 
M03-13 cells, grown to semi confluence in 60mm dishes in DMEM 4.5g/L 
glucose, were stimulated with 100 nM of PMA. The cells were kept in a 5% 
CO2 and 95% air atmosphere at 37° C for 1day or 4 days and after the 
differentiation markers were analyzed by Western-blotting or by flow 
cytometric analysis. 
 
3.3 Patients 
In the study were included men and women between 15 and 50 years of 
age who meet all the following criteria: 
• diagnosis of relapsing/remitting MS, according to McDonald 
criteria; 
• an Expanded Disability Scale Score (EDSS) between 0 and 5.0; 
• lesions detected by MRI compatible with the diagnosis of MS; 
• at least one acute episode in the last 12 months. 
The control subjects are patients with neurological diseases that need 
differential diagnosis with MS (cerebral cancers, stroke, vasculitis, etc.) 
selected by sex and age similar to MS patients. 
From each patient was collected a blood sample to purify the IgG fractions 
from blood serum. 
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The hospitals that have collaborated to our project are: 
• Cardarelli Hospital, Naples -Department of Neurology- Dr. C. Florio; 
-Department of Neurophysiopathology- Dr. F. Habetswallner; 
• Polyclinic Federico II University, Naples -Department of Neurology- 
Prof. Orefice. 
 
The MS patients were divided into two subsets according to whether or not 
the patient was in the active phase of the disease at the time of collection of 
CSF and blood.  
The attribution to the subset of patients with Poussé is established on the 
presence at least one of the following three criteria: 
- MRI brain and spinal cord in which there is evidence of at least one 
lesion absorbing contrast medium spread over a period ranging from 
24 hours before to 24 hours after taking the CSF or blood 
- Increase in 'index of albumin calculated at the time of sampling 
- Symptoms with onset no later than 48 hours and no earlier than 24 
hours prior to the withdrawal or SM type PP and SP. 
 
3.4 Purification of Immunoglobulins 
The purification of IgG fractions from serum of MS and control subjects will 
be carried out by affinity chromatography on A/G Sepharose columns 
(Pierce, Rockford, IL). The protein concentration of immunoglobulin 
fractions thus prepared will be assessed spectrophotometrically and used 
in oligodendrocyte differentiation cell models. 
 
3.5 Immunoglobulins treatment 
To check the effect of IgG fractions stimulation on the molecular 
mechanisms related to the cell maturation processes, the M03-13 cells, 
grown in FBS-free DMEM 4.5g/L glucose, supplementing with 100nM of 
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PMA, were stimulated with 200µg/ml of serum IgG from MS patients and 
control group for 30 minutes. The differentiation markers were analyzed 
by Western-blot, 
 
3.6 Protein extraction 
The RIPA buffer was used to extract the proteins from mammalian cells. A 
cocktail of protease inhibitors (Roche, USA) was added to the buffer to 
prevent the protein degradation during the extraction procedure. 
RIPA buffer: 
• 50 mM Tris-HCl, pH 7.5 
• 150 mM NaCl 
• 1% NP-40 
• 0.5% Deoxycholic acid (DOC) 
• 0.1% Sodium Dodecil Sulfate (SDS) 
• 2.5mM Sodium Pyrophosphate (SPP) 
• 1mM β-Glycerophosphate  
• 1mM Sodium Orthovanadate (NaVO4) 
• 1mM Sodium Fluoride (NaF) 
• Protease inibitor (1X) 
• 0.5mM Phenyl-methane-sulfonyl-fluoride (PMSF)  
The cells were detached from the dishes with a scraper using the RIPA 
buffer in appropriate doses depending on the number of cells (100μl RIPA 
buffer per 5 · 105 cells), on ice. Then, to achieve a complete lysis, cells were 
kept for 15min at 4°C and disrupted by repeated aspiration (for 
approximately 10 times) through a 21-gauge needle. The extract 
preparations were centrifuged at 13000 rpm for 15 minutes at 4° C and the 
pellets were discarded. The Lowry protein assay was used to determine 
the protein concentration. 
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3.7 Protein determination 
The Lowry protein assay was used for determining the total level of 
protein in a solution. The total protein concentration is exhibited by a color 
change of the sample solution in proportion to protein concentration, 
which can then be measured using colorimetric techniques. It is named for 
the biochemist Oliver H. Lowry who developed the technique in the 1940s. 
His 1951 paper describing the technique is among the most-highly cited 
papers in biology. The method combines the reactions of cupric ions with 
the peptide bonds under alkaline conditions (the Biuret test) with the 
oxidation of aromatic protein residues. The Lowry method is best used 
with protein concentrations of 0.01-1.0 mg/mL and is based on the 
reaction of Cu+, produced by the oxidation of peptide bonds, with Folin-
Ciocalteu reagent (a mixture of phosphotungstic acid and 
phosphomolybdic acid in the Folin-Ciocalteu reaction). The reaction 
mechanism involves reduction of the Folin reagent and oxidation of 
aromatic residues (mainly tryptophan, also tyrosine). The concentration of 
the reduced Folin reagent is measured by absorbance at 660 nm. As a 
result, the total concentration of protein in the sample can be deduced 
from the concentration of Trp and Tyr residues that reduce the Folin 
reagent. A reference standard was performed on four samples with 
increasing concentrations of Bovine Serum Albumin (BSA). 
 
3.8 Trasfection 
The cells were transfected with a plasmid containing the gene that 
expresses the 5-HT2A receptor conjugated to a green fluorescent protein, 
GFP, linked to the C-terminal of the receptor. 
One day before transfection, 450.000 cells (HEK293) grown to semi 
confluence in 35mm dishes in growth medium so that cells will be 70-90% 
confluent at the time of transfection. 
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For each transfection sample, prepare complexes as follows: 
• Dilute 1 γ/λ DNA (5-HT2a receptor coniugated to GFP)  in 80μl of 
growth medium without serum and antibiotics. Mix gently. 
• Dilute 4 µl of Lipofectamine™ 2000 in 80 μl of growth medium 
without serum and antibiotics. 
• Combine the diluted DNA with diluted Lipofectamine™ 2000 (total 
volume = 160 μl). Mix gently and incubate for 45 minutes at room 
temperature. 
Add the 160 μl of complexes to each dishes containing cells and medium.  
Incubate cells at 37°C in a CO2 incubator for 18-48 hours prior to testing 
for transgene expression. Medium may be changed after 4-6 hours. 
 
3.9 Flow cytometric assay for binding 5-HT2aR and IgG serum 
The HEK293 cells were plated in 100mm Petri dishes and grown to semi 
confluence. After trypsinization and wash in PBS,  these cells were 
resuspended in 200µl PBS and then incubated with mouse serum for 30 
min at 4 °C, to block non specific binding; then, were incubated for 30 min 
with 200µg of serum IgG (MS or neurological),  and stained for 30 min with 
PE-conjugated goat anti human IgG. Cells were washed and resuspended in 
200 µL of PBS for flow cytometric analysis of phycoerythrin positive cells 
with a FCSscan apparatus (Becton-Dickinson).  
Data were analyzed using WinMDI 2.8 software. 
 
3.10 Western-blotting analysis 
50 μg of total cells lysates were subjected to SDS-PAGE under reducing 
conditions using precast gels 4-12% gradient (Invitrogen). The protein 
samples were heated at 70º C and loaded on the gel. After electrophoresis, 
the proteins were transferred onto a PDVF filter membrane (Invitrogen) 
with a Trans-Blot Cell (Invitrogen) and transfer buffer containing 25 mM 
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Tris, 192 mM glycine, 20% methanol. The transfer was carried out at 4°C 
for 75 minutes at 40V. Membranes were placed in Blocking buffer 
(Invitrogen) at 4° C over-night to block the nonspecific binding sites. Filters 
were incubated with specific antibodies before being washed two times in 
water. Then, the filter was washed with wash buffer 3 times for 5 minutes 
and incubated with a peroxidase-conjugated secondary antibody 
(Invitrogen). After washing with wash buffer, peroxidase activity was 
detected with the Chemiluminescent Western Blot Immunodetection Kit 
(Invitrogen). The filters were also probed with an anti α-Tubulin antibody 
(Sigma, USA). Protein bands were revealed by ECL and, when specified, 
quantified by densitometry using ScionImage software. Densitometric 
values were normalized to α-tubulin. 
 
3.11 RT-PCR analysis 
Total RNA was extracted from 10 mm petri dish cells by using Trizol 
solution (Invitrogen, Carlsbad, CA, USA). Total RNA was treated with 
DNase. RNA concentration and quality were determined by agarose gel 
electrophoresis and spectrophotometry. The RNA was re-suspended in 50 
ml diethyl pyrocarbonate treated water, and stored at -80 °C until used. 
The synthesis of cDNA was performed by using a reverse transcription 
(RT) system (Promega). The primers used for the detection of human 5-
HT2aR mRNA were: forward 5’-TCATCATGGCAGTGTCCCTA-3’ and reverse 
5’-TGAGGGAGGAAGCTGAAAGA-3’. To rule out the possibility of amplifying 
genomic DNA, one PCR was carried out prior RT of the RNA. As internal 
control for RT and reaction efficiency, amplification of a 597 bp fragment of 
Human β-actin mRNA was carried out in parallel in each sample, using the 
primer pair: forward 5’-TCACCCTGAAGTACCCCATC -3’ and reverse 5’-
GGCTGGAAGAGTGCCTCA-3’. As a negative control for all reactions, distilled 
water was used in place of cDNA. The PCR products were separated on a 
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2% agarose gel and visualized by ethidium bromide, using a 1 kb DNA 
ladder to estimate the band sizes. Finally, the bands were cut off from the 
gel, purified and sequenced by the Primm (Milan, Italy). 
 
3.12 Statistical analysis 
Statistical differences were evaluated using a Student’s t-test for unpaired 
samples. 
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CHAPTER IV 
RESULTS 
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4.1 Molecular analysis of oligodendrocyte differentiation 
Immunocytochemistry and immunohistochemistry studies indicate that in 
chronic demyelinating lesions of MS patients the number of pro and 
mature oligodendrocytes (OL) is reduced  and there is a significant fraction 
of oligodendrocyte precursors (OPCs), suggesting an impairment of OPCs 
differentiation in MS (66, 67). To assess the presence in the serum of MS 
patients of factors that alter the differentiation of OPCs, we isolated the 
immunoglobulin fraction (Ig) from serum of MS patients and exposed to 
these fractions growing or differentiating oligodendrocytes.  The cell line 
we used was M03-13 cells, which display several features of OPCs and 
differentiate in OLs after stimulation with Phorbol-12-Myristate-13-
Acetate (PMA, an activator of PKC). 
We have, previously partly characterized PMA induced differentiation in 
M03-13 cells by assessing. 1. the levels and the localization of the 
transcription factor, Olig2 and the myelin basic protein, MBP;  2. the 
activation of ERK1/2 and CREB and; 3. the levels of  α-SMA, which 
disappear when oligodendrocytes differentiate (86). 
Figure 6 shows the morphological changes of the cells exposed to PMA 
100nM: differentiating cells are characterized by inhibition of migration 
and the appearance of multiple cytoplasmic extensions. 
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Figure 6. Optical microscope image. M03-13 undifferentiated (Undiff. M03-13) and differentiated 
(Diff. M03-13) for 4 days with PMA 100nM in the absence of serum. 
 
 
 
The differentiation of the cells exposed to 100nM PMA for 1 day is marked 
by a significant reduction of α-SMA levels (a negative differentiation 
marker) and by the activation of ERK1/2 (P-ERK1/2) and the cAMP-
transcription factor CREB (P-CREB) (positive differentiation markers) 
(Figure 7). 
 
 
Figure 7. Modulation of differentiation markers  in M03-13 cells stimulated with PMA for 1d. 
Western blotting analysis of α-SMA, P-ERK1/2, P-CREB and Olig-2 levels in M03-13 cells after 1 day 
of differentiation with 100nM PMA in medium without serum. N.D., indicates Not Differentiated 
cells, growing in complete medium, Diff., indicates Differentiated cells. 
The histograms show the values (means ± SEM) relative to N.D. obtained by densitometric analysis 
of protein bands normalized to α-Tubulin in three independent experiments. *p<0.05 vs N.D.; 
**p<0.01 vs N.D. 
On the left a representative experiment is shown. 
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The levels of MBP, a specific marker of mature oligodendrocytes, assessed 
by flow cytometry, progressively increase 1 and 4 days of exposure to PMA 
(Figure 8). 
 
 
Figure 8. Increasing levels of MBP protein at different days of differentiation of M03-13 cells 
with PMA. 
Immunoreactivity for MBP was evidenced by indirect immunofluorescence and flow cytometry, 
using primary antibodies against MBP and CY3-conjugated anti rabbit IgG as secondary antibodies. 
Control was treated with secondary antibodies alone. 10,000 cells were counted for each sample. 
N.D. indicates Not Differentiated cells, growing in complete medium, Diff., indicates Differentiated 
cells. 
The histograms show the mean ± SEM of three independent experiments. *p<0.01 vs N.D.  
On the left a representative is shown. 
 
 
The levels of P-ERK1/2 and P-CREB in M03-13 cells were induced by 
differentiation, with a peak at 1 day; conversely, a progressive decrease of -
SMA levels was observed during differentiation (Figure 9). 
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Figure 9. P-CREB and α-SMA levels in M03-13 cells during differentiation with PMA. 
Western blotting analysis of P-CREB and α-SMA levels in M03-13 cells after 1, 2 and 4 days of 
differentiation of M03-13 cells with 100nM PMA in medium without serum. N.D. indicates Not 
Differentiated cells, growing in complete medium. The histogram shows the values (means ± SEM) 
relative to N.D. obtained by densitometric analysis of protein bands normalized to α-Tubulin of 
three independent experiments. *p<0.01 vs N.D.  
On the left a representative experiment is shown. 
 
Figure 10 shows that P-ERK1/2 levels are progressively induced by 
differentiation. 
 
Figure 10. P-ERK1/2 levels in M03-13 cells during differentiation with PMA  
Western blotting analysis of P-ERK1/2 levels in M03-13 cells after 1, 2 and 4 days of differentiation 
of M03-13 cells with 100nM PMA in medium without serum. N.D. indicates Not Differentiated cells, 
growing in complete medium. 
The histogram shows the values (means ± SEM) relative to N.D. obtained by densitometric analysis 
of protein bands normalized to α-Tubulin of three independent experiments. *p<0.01 vs N.D.  
On the left a representative experiment is shown 
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4.2  The Ig fraction isolated from MS patients inhibits PMA-
induced differentiation of oligodendrocytes 
We hypothesized that serum of MS patients may contain molecules that 
interfere  with oligodendrocyte differentiation. To this end we incubated 
M03-13 cells for 30 minutes with PMA (100nM), in the absence of serum. 
Under these conditions oligodendrocyte exit the cell cycle and 
progressively differentiate (pro-differentiative conditions). We exposed 
differentiated oligodendrocytes to the IgG fraction (200 µg/ ml), purified 
by affinity chromatography from serum of MS and control patients. 
Controls patients were subjects with neurological diseases needing 
differential diagnosis with MS (cerebral cancers, stroke, vasculitis, etc.). 
The expression levels of P-ERK1/2 were assessed by Western-blotting. 
The differentiation marker, p-ERK1/2, increased progressively with 
differentiation and was not modified by exposure of the cells to the  to IgG 
derived from control patients. M03-13 cells incubated in the presence of 
IgG purified from serum of  MS patients instead, showed a significant  
reduction of P-ERK1/2 levels (Figure 11). 
It was observed production of intrathecal IgG presents in 90% of patients 
with MS and the presence of oligoclonal bands (OCB) ; studies in the early 
stages of disease suggest that in the acute phase of the disease (Poussè) 
most of the lesions is preceded by focal destruction of blood brain barrier 
(BBB); therefore, this condition would facilitate entry of autoreactive T 
cells and of exit of intratecal antibodies outside the CNS (36). For this 
reason, we, also, evaluated the different effects of IgG from MS in the active 
phase (Poussè) and in quiescent phase (Not Poussè); the P-ERK1/2 levels 
in cells incubated with IgG from MS patients in the active phase (Poussè) 
were significantly lower compared to cells stimulated with IgG of control 
patients; on the contrary, there was no significantly difference of P-ERK1/2 
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levels between Not Poussè and Differentiated or Differentiated with IgG Ctr 
groups. 
 
 
 
Figure 11. IgG from MS patients inhibit PMA effect on p-ERK1/2 levels. 
Western blotting analysis of p-ERK1/2 levels in M03-13 cells stimulated with PMA (100 nM) for 30 
minutes in serum-free medium in the presence of IgG (200 µg/ml) purified from the serum of 
patients.  
N.D. indicates Not Differentiated cells, growing in complete medium; Diff. was treated only with PMA 
(100 nM) for 30 minutes in serum-free medium; Ig Ctr indicates cells stimulated with IgG of control 
patients (n=6); Ig MS indicates cells stimulated with IgG of patients with MS (n=10); Poussè and Not 
Poussè indicate cells stimulated with IgG from MS patients in the active (n=5) and quiescent phase 
of disease (n=5), respectively. 
The histograms show the values (means ± SEM) relative to Diff. obtained by densitometric analysis 
of protein bands normalized to α-Tubulin of three independent experiments. *p<0.05 vs N.D; # 
p<0.05 vs Diff and vs Diff+IgG Ctr.; ## p<0.01 vs Diff. and vs Diff.+IgG Ctr. 
 
Using the same protocol, we monitored the effects of IgG from MS patients 
on P-CREB levels. 
In M03-13 cells, after 30 minutes of stimulation with PMA (100 nM) in the 
absence of serum, the P-CREB levels were increased compared to growing 
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cells (N.D.); in cells treated for 30 minutes with PMA, in the presence of IgG 
from MS patients, the P-CREB levels were decreased (Figure 12). Moreover, 
the P-CREB levels in cells incubated with IgG from MS patients in the active 
phase (Poussè) were significantly lower compared to IgG from control 
patients; on the contrary, not statistically significant differences were 
observed between IgG from MS patients in the silent phase (Not Poussè) 
and that from controls. 
 
 
 
Figure 12. IgG from MS patients inhibit PMA effect on p-CREB levels. 
Western blotting analysis of p-CREB levels in M03-13 cells stimulated with PMA (100 nM) for 30 
minutes in serum-free medium in the presence of IgG (200 µg/ml) purified from the serum of 
patients.  
N.D. indicates Not Differentiated cells, growing in complete medium; Diff. was treated only with PMA 
(100 nM) for 30 minutes in serum-free medium; Ig Ctr indicates cells stimulated with IgG of control 
patients (n=6); Ig MS indicates cells stimulated with IgG of patients with MS (n=10); Poussè and Not 
Poussè indicate cells stimulated with IgG from MS patients in the active (n=5) and quiescent phase 
of disease (n=5), respectively. 
The histograms show the values (means ± SEM) relative to Diff. obtained by densitometric analysis 
of protein bands normalized to α-Tubulin of three independent experiments. *p<0.05 vs N.D, # 
p<0.05 vs IgGCtr 
 
5-HT2a receptor pathway in oligodendrocyte differentiation 
47 
 
Further experiments for the analysis of late effects of biological samples on 
cellular maturation processes of OLs, were performed by incubating M03-
13 cells for 1 day with PMA (100 nM), in the absence of serum (pro-
differentiative conditions), and in the presence of IgG (200 µg/ ml), 
purified by affinity chromatography, from the serum of MS and control 
patients. 
In this case the expression levels of oligodendrocyte transcription factor, 
Olig-2, were assessed by Western-blotting. Olig-2 increased as a result of 
differentiation; in cells incubated in the presence of IgG purified from 
serum of patients with MS, the levels were lower than that observed after 
treatment of cells with IgG from control patients (Figure 13). 
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Figure 13 IgG from MS patients inhibit PMA effect on Olig-2 levels  
Western blotting analysis of Olig-2 levels in M03-13 cells stimulated with PMA (100 nM) for 1 day in 
serum-free medium in the presence of IgG (200 µg/ml) purified from the serum of patients.  
N.D. indicates Not Differentiated cells, growing in complete medium; Diff. was treated only with PMA 
(100 nM) for 1 day in serum-free medium; IgG Ctr indicates cells stimulated with IgG of control 
patients; Ig MS indicates cells stimulated with IgG of patients with MS. 
The histograms show the values (means ± SEM) relative to Diff. obtained by densitometric analysis 
of protein bands normalized to α-Tubulin of  three independent experiments. 
* p<0.01 vs ND; **p< 0.05 vs IgGCtr. 
 
 
Subsequently, we evaluated the effects of IgG from MS patients in the acute 
and quiescent phase of disease on Olig-2 levels. 
In particular, we evaluated the effect of IgG derived from serum of 11 
control patients, 6 patients with MS during the active phase (Poussè) and 5 
patients with MS quiescent (Not Poussè). Even in this case M03-13 cells 
were maintained in culture for 24h with PMA in the presence of IgG 
extracted from serum before the Western blotting analysis of Olig-2 levels. 
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As it is shown in Fig.14, the Olig-2 levels in cells incubated with IgG from 
MS patients in the active phase (Poussè) were significantly lower 
compared to IgG from controls patients; on the contrary, not statistically 
significant differences were observed between IgG  from MS patients in the 
silent phase (Not Poussè) and that from controls. 
 
 
 
Figure 14 Modulation of Olig-2 levels in M03-13 cells stimulated with IgG from MS patients 
during phase Poussè and Not Poussè. 
Western blotting analysis of Olig-2 levels in M03-13 cells after 1 day of differentiation of M03-13 
cells with 100nM PMA in medium without serum and stimulated with IgG (200 µg/ml)  purified 
from the serum of patients  
N.D. indicates Not Differentiated cells, growing in complete medium; Diff. was treated only with PMA 
(100 nM) for 1 day in serum-free medium; IgG Ctr indicates cells stimulated with IgG of control 
patients (n=6); Poussè and Not Poussè indicate cells stimulated with IgG from MS patients in the 
active (n=5) and quiescent phase (n=5) of disease, respectively. 
The histograms show the values (means ± SEM) relative to Diff. obtained by densitometric analysis 
of protein bands normalized to α-Tubulin of three independent experiments. *p <0.01 vs ND; # 
p<0,05 vs Diff and vs Diff + Ig Ctr 
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4.3  Serotonin (5-HT) induces differentiation of oligodendrocytes 
To dissect the signalling pathways targeted by these IgG from active MS 
patients, we investigated the activity of several G protein coupled  and 
tyrosine signalling receptors in oligodendrocytes. We focused our 
attentention to the serotonin receptor 2A, because human embryonic 
oligodendrocyte progenitors express this receptor (85). We first, analysed 
the expression of the receptor in various tissues and cell lines. We first, 
analysed the expression of the receptor in various tissues and cell lines. 
a. Expression of 5 HT receptor 
M03-13 cells express the 5-HT2a receptor  as protein (Fig. 15A) and as 
mRNA (Fig. 15B). Western Blotting analysis shows that receptor protein is 
also expressed in human, rat and mouse brain and in several neuronal cell 
lines,  such as SK-N-BE, SH-SY5Y, U87 and Hela cells (Fig.15A). Conversely, 
the human embryonic  kidney cell line , HEK293, did not express either 5-
HT2aR both as protein (Figure 15A) and as mRNA (Fig. 15B).  
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A 
 
B 
 
Figure 15 Expression of the 5-HT2aR in different cell lines and tissues. 
The panel A shows the Western Blotting analysis of  5-HT2a receptor protein in different tissues and 
several cell lines; the panel B  shows the RT-PCR analysis of the expression of 5-HT2a receptor 
mRNA in two different cell lines (HEK 293 and M03-13). As internal control for RT and reaction 
efficiency, amplification of fragment of Human β-actin mRNA was carried out in parallel in each 
sample. 
 
 
b. HT stimulates the early oligodendrocytes differentiation markers 
The M03-13 cells express the 5-HT2a receptor (Fig.11). To ascertain 
whether 5-HT induced oligodendrocyte differentiation, we exposed the 
oligodendrocyte cell line cells to 5μM 5-HT or to 100nM PMA s and 
examined the effects on P-ERK1/2 and Olig-2, as markers of OL 
differentiation.  
Figure 16 shows that 5HT induced a sharp P-ERK1/2 peak at 15-30 min, 
which returned to the un-stimulated levels 2 h after the initial stimulation. 
Conversely, the P-ERK1/2 induction by PMA persisted at least 2h. 
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Using the same protocol, we monitored the effects on Olig-2 expression of 
5μM of 5-HT or 100nM PMA. Olig-2 levels were induced after 15 min of 
stimulation with 5-HT and then decreased when the cells were exposed for 
longer period to 5 HT, returning to basal levels after 2h. On the contrary, 
PMA induced Olig-2 with a sharp peak at 15 min and after a transient drop 
at 1 h, stimulated Olig-2 levels for 24h (Fig. 14 and ref 15). 
Figure 16 shows that 5HT induced a sharp P-ERK peak at 15-30 min, which 
returned to the un-stimulated levels 2 h after the initial stimulation. 
Conversely, the P-ERK1/2 induction by PMA persisted at least 2h.  
 
 
 
Figure 16. Modulation  of P-ERK1/2  levels in M03-13 cells stimulated with 5-HT and PMA. 
The cells were incubated for 16 hours in medium containing 0.2% of FBS (Ctr) and then stimulated 
with 5μM 5-HT or 100nM PMA in medium without serum for the times indicated before harversting 
them for Western blotting analysis of P-ERK1/2 levels. The graph shows the values (means ± SEM) 
relative to control obtained by densitometric analysis of protein bands normalized to α-tubulin of 
three independent experiments. *p<0.01 vs Ctr, **p<0.05 vs Ctr. 
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Using the same protocol, we monitored the effects on Olig-2 expression of 
5μM of 5-HT or 100nM PMA. Olig-2 levels were induced after 15 min of 
stimulation with 5-HT and then decreased when the cells were exposed for 
longer period to 5 HT, returning to basal levels after 2h. On the contrary, 
PMA induced Olig-2 with a sharp peak at 15 min and after a transient drop 
at 1 h, stimulated Olig-2 levels for 24 h (Fig. 13 and 14). 
 
 
 
 
Figure 17. Modulation of Olig-2 levels in M03-13 cells stimulated with 5-HT or PMA. 
The cells were incubated for 16 hours in medium containing 0.2% of FBS (Ctr) and then stimulated 
with 5μM 5-HT or 100nM PMA in medium without serum for the indicated times before harversting 
them for Western blotting analysis of Olig-2 levels. The graph shows the values (means ± SEM) 
relative to control obtained by densitometric analysis of protein bands normalized to α-tubulin of 
three independent experiments. *p<0.01 vs Ctr, **p<0.05 vs Ctr 
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c. Engineering heterologous cell lines expressing the 5HT 
receptor  
To verify the ability of serum IgG from MS patients to interfere with 5-
HT2a receptor signaling, we transfected with the recombinant 2aHt 
receptor  the human embryonic kidney cells (HEK 293) , which do not 
express the endogenous receptor. The cells were transiently transfected 
with an expression vector encoding the 5-HT2a receptor cDNA fused to the 
green fluorescent protein, GFP. The fusion protein contained GFP linked to 
the C-terminal of the receptor, leaving the N-terminal portion available for 
ligand binding. The transfection efficiency (approximately 80% at 24 h) 
was assessed by cytofluorimetry.  
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Figure 18. The serotonin induces levels of P-ERK1/2 levels in HEK293 cells transfected with 
5-HT2A-GFP construct. 
The cells were transfected and after 24h, incubated for 4h in medium containing 0.2% FBS and then 
stimulated with 5μM of 5-HT for 15 minutes, before harvesting them for Western blotting analysis of 
P-ERK1/2 levels. Grow indicates cells  growing in complete medium; st 0,2% indicates cells 
incubated with medium containing 0,2% FBS for 4 h The histograms show the values (means ± SEM) 
relative to GFP obtained by densitometric analysis of protein bands normalized to α-tubulin of three 
independent experiments. *p < 0.01 vs 5-HT2aR 
In the lower part of the figure a representative experiment in shown 
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Subsequently, we tested whether the stimulation of cells with the receptor 
agonist, serotonin, for 15 minutes at a concentration of 5μM, induced P-
ERK1/2 levels. 
In transient transfected cells (5-HT2aR-GFP construct) exposed to 
serotonin robustly activated ERK1/2 (Fig.18), whereas control transfected 
cells (GFP construct) did not respond to 5HT (data not shown). 
 
4.4 IgGs from MS patients selectively inhibit ERK1/2 activation 
by serotonin in HEK293cells transiently or stably expressing 
the 5-HT2a receptor  
After testing the functionality of the system, we studied the effects 
of preincubation of the cells with human IgG derived from MS or 
neurological patients on 5-HT2aR signaling. HEK293 cells, transiently 
expressing the 5-HT2a receptor-GFP fusion protein, were exposed to MS 
IgG for 30 minutes and subsequently with 5Ht for 15 minutes.  P-ERK1/2  
levels in these cells was significantly inhibited by MS IgG. The same cells 
pre-incubated with IgG from control patients and 5Ht did not change the 
pERK1/2 levels. Inhibition of 5 HT-induced ERK1/2 by MS IgG was highly 
reproducible and well controlled, since the levels of pERK1/2 were 
normalized to total ERK1/2 and to 5-HT2AR expression in transfected 
cells. Also, not-transfected or control transfected cells did not respond to 
5HT or MS IgG (Fig.18, legend). 
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Figure 19. Effect of serum IgG from MS and neurological patients on P-ERK 1/2 levels in 
transient 5-HT2aR transfected cells 
The HEK293 cells transfected in transient with 5-HT2aR-GFP were incubated for 4h in medium 
containing 0.2% FBS. Then the cells were pre-incubated for 30 minutes with serum IgG (3 MS and 2 
neurological) and subsequently stimulated with 5μM of 5-HT for 15 minutes, before harversting 
them for Western blotting analysis of P-ERK1/2 levels. The histograms show the values (means ± 
SEM) relative to control (5-HT2aR + 5-HT) obtained by densitometric analysis of protein bands 
normalized to α-tubulin and 5-HT2a receptor of three independent experiments. *p < 0.01 vs 5-
HT2aR; # p < 0.01 vs 5-HT2aR + 5-HT; ## p< 0.05 vs 5-HT2aR + 5-HT 
In the lower part of the figure a representative experiment in shown.  
 
 
The serotonin receptor 5-HT2a is not present in the HEK 293 cells, but the 
efficiency of transient transfection, although very high and reproducible, is 
a variable to be considered in every single experiment. To minimize this 
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variable, was created a cellular model of HEK293 stably transfected with 
the 5-HT2aR-GFP construct on which functional tests have been 
performed, analyzing the P-ERK1/2 levels after 5-HT stimulation. 
As in previous experiments, the cells stably transfected with 5-HT2aR-
GFP were stimulated for 30 minutes with serum-IgG of patients with MS 
and of patients with neurological diseases, and subsequently stimulated for 
15 minutes with serotonin (5-HT). 
Figure 20 shows that serotonin was able to induce pERK1/2 and that 
selectively, MS IgG inhibited this induction. Under the same conditions 
control cells did not respond to 5Ht or MS IgG. 
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Figure 20 Effect of serum IgG from MS and neurological patients on P-ERK 1/2 levels in stably 
transfected cells. 
The HEK293 cells stably transfected with 5-HT2aR-GFP were incubated for 4h in medium 
containing 0.2% FBS. Then the cells were pre-incubated for 30 minutes with serum Ig (2 MS and 1 
neurological) and subsequently stimulated with 5μM of 5-HT for 15 minutes, before harversting 
them for Western blotting analysis of P-ERK1/2 levels. The histograms show the values (means ± 
SEM) relative to control (5-HT2aR) obtained by densitometric analysis of protein bands normalized 
to α-Tubulin and 5-HT2a receptor of  three independent experiments. *p < 0.05 vs 5-HT2aR; # p < 
0.05 vs 5-HT2aR + 5-HT; ## p< 0.01 vs 5-HT2aR + 5-HT. 
In the lower part of the figure a representative experiment in shown 
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4.5 Presence in MS serum of HT2a receptor binding antibodies 
The experiments shown above indicate that in the serum of MS patients are 
present IgG, able to interfere with oligodendrocyte differentiation, possibly 
through the 5Ht receptor. If this is the case, cells expressing the 5Ht 
receptor should be able to bind selectively serum IgG from MS not control 
patients, assayed  by  flow cytometry.  
Cytofluorimetry was performed on HEK 293 cells transiently transfected 
with the 5-HT2aR-GFP.  
The cells were incubated for 30 min with 200µg of serum IgG (MS or 
control) and subsequently challenged for 30 min with phycoerythrin-
conjugated (PE) anti human IgG. 
Figure 21 shows that PE fluorescence, which is a measure of  IgG binding, 
marked a significant fraction of cells in the sample incubated with IgG from 
MS compared to the control samples (Figure 21 and Table 1). These data 
suggest that there is a specific binding between 5-HT2a receptor 
expressing cells and MS IgG and point furthermore  to a possible specific 
assay to purify antibodies recognizing the 5-HT receptor. 
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Figure 21. Binding between serum IgG from neurological or MS patients and 5-HT2a receptor.  
5-HT2aR-GFP transfected cells were resuspended in 200µl PBS and then incubated with mouse 
serum for 30 min at 4 °C, to block non specific binding.  
Then cells were incubated for 30 min with 200µg of serum IgG (MS or neurological), and stained for 
30 min with PE-conjugated goat anti human IgG. Cells were washed and resuspended in 200 µL of 
PBS for flow cytometric analysis. 
 
 % gated in HEK293 not 
trasfected 
% gated in HEK293 
trasfected (5-HT2aR-GFP) 
IgG neurological 0,5% 28% 
IgG MS 0,8% 77% 
Table 1. Quantitative analysis of the Figure 21. 
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CHAPTER V 
DISCUSSION AND 
CONCLUSIONS 
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Multiple sclerosis (MS) is a chronic demyelinating disease affecting 
oligodendrocytes (OLs), the cells responsible for axon myelination in the 
CNS. OLs originate from progenitor cells (OPCs) with migratory and mitotic 
capacity, maturing in postmitotic myelin-producing cells. In chronic MS 
lesions OPCs accumulate with loss of mature myelinating cells suggesting 
the existence of a differentiation block of OPCs, that may contribute to the 
reduction of OLs and to the limited remyelination in MS. These data is 
actually based on immunocytochemistry and immunohistochemistry 
investigations of the brain tissues, but the cellular mechanisms underlined 
to the failure of OLs maturation observed in MS has not been clarified. 
In the first part of the project we verified the hypothesis of the presence, in 
serum of MS patients, of autoantibodies impairing the differentiation of 
OPCs. In MS patients, it has been demonstrated a disruption of the BBB; 
therefore, it is possible to hypothesize that serum antibodies can reach the 
CNS, producing demyelination. Based on these assumptions, through the 
analysis of the expression levels of differentiation markers, were analyzed 
the effects of  serum IgG from MS patients on the OLs differentiation. 
For the experiments we used the human oligodendrocyte cell line MO3-13. 
These cells were previously characterized in our laboratory. We identified 
several molecular markers modulated by differentiation stimuli such as 
PMA (PKC activator) identifying  the effective concentrations and the 
incubation  time required for the modulation of differentiation markers 
following the pattern of their expression over time up to 4 days of 
treatment (Figs 7-8-9-10).  
Using IgG from serum of MS patients to stimulate the cells, we found that P-
ERK1/2, P-CREB and Olig-2 expression levels were significantly reduced 
compared with that of cells stimulated with IgG from control group (Figs 
11-12-13-14).  
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The immune mechanisms leading to demyelination in MS are still unknown 
and the autoimmune hypothesis itself is not certain.  
According to the hypothesis defined "outside-in", the onset of lesions are 
preceded by focal destruction of BBB that allows to autoreactive T cells and 
antibodies to reach CNS. This theory is opposed to the "inside-out" 
hypothesis. According to this hypothesis, an injury of the cells within CNS 
triggers an inflammatory response leading to pro-inflammatory lesions of 
the BBB that allows the entry of immune cells in CNS and their activation 
(80).  
Studies of magnetic resonance imaging (MRI) in the early stages of the 
disease suggest that the focal destruction of the BBB is a hallmark of the 
acute phase of disease (Poussè) (81). 
For this reason, we also compared the effects of IgG from MS patients in the 
active phase (Poussè) and in quiescent phase of disease on the OLs 
differentiation. We found that the P-ERK1/2, P-CREB and Olig-2 levels in 
cells incubated with IgG from MS patients during  Poussè were reduced 
compared with that isolated during the quiescent phase of disease (Figs 
11-12-14). 
In the second part of the project we investigated the hypothesis of the 
presence, in MS patients, of autoantibodies directed concomitantly against 
a virus and a membrane receptor used by the virus to infect the OL, leading 
to differentiation failure.  
The identification of a putative receptor target of molecules present in the 
biological fluids of MS patients will pave the way to dissect the primary 
cause of the disease.  
A candidate receptor expressed in oligodendrocytes is the 5-HT2aR 
subtype of the serotoninergic 5-HTR family. This receptor is used by 
human polyomavirus JC (JCV) to enter human embryonic stem cell-derived 
olygodendrocyte progenitor cells. JCV causes progressive multifocal 
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leukoencephalopathy (PML), a fatal demyelinating disease, in 
immunocompromised patients. The serotonergic receptor 5HT2A could act 
as the cellular receptor for JCV on human glial cells. In fact  the 
administration of 5HT2A receptor antagonists inhibited JCV infection  and 
monoclonal antibodies directed at 5HT2A receptors blocked infection of 
glial cells by JCV (82).  
This virus may be involved in the disease. Two features of the biology of 
JCV make it a suitable candidate for MS: its neurotropic capability of 
targeting glial cells, and its latency and persistence. Recent studies have 
demonstrated that 70% of the human population worldwide is infected 
with JCV but the virus is absent from CSF of normal or neurological 
patients while is present in some MS subjects (83). 
On the basis of these studies, we had to verify the involvement of 5-HT2a 
receptor signalling in OL differentiation and the direct interaction of 5-
HT2a receptor with serum-Ig from MS patients, which might lead to an 
alteration of downstream oligodendrocytes intracellular signalling 
inducing differentiation block.  
The 5-HT2A receptor is a seven transmembrane receptor activating 
phospholipase C (PLC), through Gq ,  leading to accumulation of IP3, di-
acylglycerol (DAG) and activation of protein kinase C (PKC). Increase in 
cytoplasmic IP3 causes a release of calcium from intracellular endoplasmic 
reticulum stores, and activaction of MAP kinase cascade (ERK1/2). 
PKC activation is the target of PMA leading to differentiation in M03-13 
cells, nevertheless, in our study we were not able to differentiate the cells 
with serotonin, probably, due to the rapid desensitization and 
internalization of the 5-HT2a receptor (84). However stimulation of M03-
13 cells with serotonin for 15 min induced early differentiation markers 
such as P-ERK1/2 and Olig-2 (Figs 16-17). 
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Using IgGs from serum of MS patients to stimulate the cells, we found that 
5-HT-mediated induction of P-ERK1/2 levels, in HEK293 cells transfected 
with 5-HT2a receptor, was significantly reduced compared with that 
stimulated with IgG from control subjects ( Figs 19-20). 
Preliminary data also suggest a direct binding of IgG from MS patients with 
5Ht2AR (Fig.21). 
In conclusion, these data demonstrate that MS-derived autoantibodies 
interfere and inhibit oligodendrocyte differentiation-induced by 5HT 
opening new perspectives in the diagnosis and therapy for MS. Further 
studies will be focused on  the purification of the whole receptor protein or  
peptides corresponding to the extracellular domains of the protein 
involved in the binding with the antibodies and/or JCV capsid protein. 
These data give the opportunity to develop new diagnostic in vitro assay 
methods to execute a specific and early diagnosis of multiple sclerosis 
based on the measure of the binding activity between the purified 
receptor/peptides and the blood serum from patients.  
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